Annual EBITDA
-$206.69 M
-$80.88 M-64.28%
December 31, 2023
Summary
- As of February 8, 2025, INBX annual EBITDA is -$206.69 million, with the most recent change of -$80.88 million (-64.28%) on December 31, 2023.
- During the last 3 years, INBX annual EBITDA has fallen by -$142.89 million (-223.98%).
- INBX annual EBITDA is now -970.67% below its all-time high of -$19.30 million, reached on December 31, 2017.
Performance
INBX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$43.10 M
-$1.91 B-102.31%
September 30, 2024
Summary
- As of February 8, 2025, INBX quarterly EBITDA is -$43.10 million, with the most recent change of -$1.91 billion (-102.31%) on September 30, 2024.
- Over the past year, INBX quarterly EBITDA has dropped by -$1.91 billion (-102.31%).
- INBX quarterly EBITDA is now -102.31% below its all-time high of $1.86 billion, reached on June 30, 2024.
Performance
INBX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$1.74 B
+$230.00 K+0.01%
September 30, 2024
Summary
- As of February 8, 2025, INBX TTM EBITDA is $1.74 billion, with the most recent change of +$230.00 thousand (+0.01%) on September 30, 2024.
- Over the past year, INBX TTM EBITDA has increased by +$230.00 thousand (+0.01%).
- INBX TTM EBITDA is now at all-time high.
Performance
INBX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
INBX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -64.3% | -102.3% | +0.0% |
| 3 y3 years | -224.0% | -9.8% | +1378.0% |
| 5 y5 years | -618.5% | -9.8% | +1378.0% |
INBX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -174.3% | at low | -102.3% | +11.8% | at high | +1194.2% |
| 5 y | 5-year | -373.9% | at low | -102.3% | +11.8% | at high | +1194.2% |
| alltime | all time | -970.7% | at low | -102.3% | +11.8% | at high | +1194.2% |
Inhibrx Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$43.10 M(-102.3%) | $1.74 B(+0.0%) |
| Jun 2024 | - | $1.86 B(-3915.1%) | $1.74 B(-1194.0%) |
| Mar 2024 | - | -$48.85 M(+72.5%) | -$159.35 M(+6.4%) |
| Dec 2023 | -$206.69 M(+64.3%) | -$28.32 M(-34.7%) | -$149.74 M(-3.3%) |
| Sep 2023 | - | -$43.33 M(+11.5%) | -$154.93 M(+9.8%) |
| Jun 2023 | - | -$38.85 M(-1.0%) | -$141.06 M(+3.4%) |
| Mar 2023 | - | -$39.25 M(+17.2%) | -$136.43 M(+8.4%) |
| Dec 2022 | -$125.82 M(+67.0%) | -$33.50 M(+13.7%) | -$125.86 M(+12.9%) |
| Sep 2022 | - | -$29.47 M(-13.9%) | -$111.46 M(+10.9%) |
| Jun 2022 | - | -$34.22 M(+19.3%) | -$100.50 M(+17.2%) |
| Mar 2022 | - | -$28.67 M(+50.1%) | -$85.78 M(+13.8%) |
| Dec 2021 | -$75.36 M | -$19.10 M(+3.2%) | -$75.36 M(+3.1%) |
| Sep 2021 | - | -$18.50 M(-5.1%) | -$73.10 M(+4.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$19.50 M(+6.8%) | -$69.93 M(+8.1%) |
| Mar 2021 | - | -$18.25 M(+8.3%) | -$64.66 M(+1.4%) |
| Dec 2020 | -$63.80 M(+46.3%) | -$16.85 M(+9.9%) | -$63.80 M(+5.1%) |
| Sep 2020 | - | -$15.33 M(+7.7%) | -$60.71 M(-1.2%) |
| Jun 2020 | - | -$14.23 M(-18.1%) | -$61.44 M(+6.3%) |
| Mar 2020 | - | -$17.39 M(+26.4%) | -$57.81 M(+33.6%) |
| Dec 2019 | -$43.62 M(+51.6%) | -$13.76 M(-14.4%) | -$43.26 M(+46.6%) |
| Sep 2019 | - | -$16.07 M(+51.7%) | -$29.50 M(+119.6%) |
| Jun 2019 | - | -$10.60 M(+273.7%) | -$13.43 M(+43.9%) |
| Mar 2019 | - | -$2.84 M(-56.3%) | -$9.33 M(-38.7%) |
| Dec 2018 | -$28.77 M(+49.0%) | - | - |
| Jun 2018 | - | -$6.50 M(-25.5%) | -$15.21 M(+74.5%) |
| Mar 2018 | - | -$8.72 M | -$8.72 M |
| Dec 2017 | -$19.30 M | - | - |
FAQ
- What is Inhibrx Biosciences annual EBITDA?
- What is the all time high annual EBITDA for Inhibrx Biosciences?
- What is Inhibrx Biosciences annual EBITDA year-on-year change?
- What is Inhibrx Biosciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Inhibrx Biosciences?
- What is Inhibrx Biosciences quarterly EBITDA year-on-year change?
- What is Inhibrx Biosciences TTM EBITDA?
- What is the all time high TTM EBITDA for Inhibrx Biosciences?
- What is Inhibrx Biosciences TTM EBITDA year-on-year change?
What is Inhibrx Biosciences annual EBITDA?
The current annual EBITDA of INBX is -$206.69 M
What is the all time high annual EBITDA for Inhibrx Biosciences?
Inhibrx Biosciences all-time high annual EBITDA is -$19.30 M
What is Inhibrx Biosciences annual EBITDA year-on-year change?
Over the past year, INBX annual EBITDA has changed by -$80.88 M (-64.28%)
What is Inhibrx Biosciences quarterly EBITDA?
The current quarterly EBITDA of INBX is -$43.10 M
What is the all time high quarterly EBITDA for Inhibrx Biosciences?
Inhibrx Biosciences all-time high quarterly EBITDA is $1.86 B
What is Inhibrx Biosciences quarterly EBITDA year-on-year change?
Over the past year, INBX quarterly EBITDA has changed by -$1.91 B (-102.31%)
What is Inhibrx Biosciences TTM EBITDA?
The current TTM EBITDA of INBX is $1.74 B
What is the all time high TTM EBITDA for Inhibrx Biosciences?
Inhibrx Biosciences all-time high TTM EBITDA is $1.74 B
What is Inhibrx Biosciences TTM EBITDA year-on-year change?
Over the past year, INBX TTM EBITDA has changed by +$230.00 K (+0.01%)